Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Genesis Research Derives Surplus

Genesis Research Derives Surplus From Fourfold Revenue Increase

Auckland, New Zealand, 31 January 2001 – Genesis Research [NZSE & ASX: GEN] today announced a Net Surplus for the year ended 31st December 2000 of $723,000. This compares with a deficit of $7.15 million for the previous year and the $9.97 million loss forecast in the company’s recent investment statement and prospectus. The improved results were achieved through Genesis sublicensing its PVAC™ vaccine for the treatment of psoriasis to partners in Japan and North America, as a result of which total operating income effectively quadrupled to $28.66 million (up 298% from $7.19 million).

The company finished the year with cash reserves of $61.93 million as a result of the receipt of these upfront licensing payments and the capital raising undertaken during the year.

In accordance with the policy of the Board, as noted in the August 2000 investment statement and prospectus, no dividend will be paid.

The increased revenues, together with the successful capital raising programme enabled Genesis to increase expenditure on research and development to $18.9 million, up 58% from $11.9 million in 1999. Funds were applied to research into new therapeutics and other potential products as well as the Phase II Clinical trials currently being conducted in USA, Brazil and Philippines. Genesis has not received the results of these trials yet but expects to announce the results of the USA trial early in February. At 31st December Genesis’ 24 hour 7 day sequencing facility had developed over 1 million EST sequences in its database. This now includes the largest forestry tree EST collection in the world, as well as specialised human, bovine, ovine, cervine, fruit tree, forage grass and microbe databases.

“As this result shows, the prime beneficiary of Genesis’ revenue growth and capital raising is our enhanced research programme,” said Founder and CEO Dr James Watson. “To operate from this solid base gives us an immense advantage in what is a highly competitive environment.”

Staff numbers rose during the year from 83 to 124 through an active national and international recruitment programme.

About Genesis
Genesis is a New Zealand-based biotechnology company whose core business is genomics – the translation and use of the chemical information carried within genes of living organisms. Genesis specialises in discovery, building EST databases from a diverse range of carefully selected gene pools, targeting genes, promoters or proteins that have commercial value through their potential ability to alter a living process or to create a new industrial process. Genesis is not a manufacturer or distributor of products: it mines these databases, and uses collaboration with industry partners, to develop innovative biotechnology products of commercial value from its discovery activities. Genesis has vaccine therapeutics in clinical trials which are novel because they can be used to treat immune disorders not generally caused by infection. Genesis also uses technologies applied in the health field to develop novel products in the areas of agriculture, horticulture and forestry in which our New Zealand primary producer partners lead the world.

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Media Mega Merger: StuffMe Hearing Argues Over Moveable Feast

New Zealand's two largest news publishers are appealing against the Commerce Commission's rejection of the proposal to merge their operations. More>>

Elsewhere:


Approval: Northern Corridor Decision Released

The approval gives the green light to construction of the last link of Auckland’s Western Ring Route, providing an alternative route from South Auckland to the North Shore. More>>

ALSO:


Crown Accounts: $4.1 Billion Surplus

The New Zealand Government has achieved its third fiscal surplus in a row with the Crown accounts for the year ended 30 June 2017 showing an OBEGAL surplus of $4.1 billion, $2.2 billion stronger than last year, Finance Minister Steven Joyce says. More>>

ALSO:

Mycoplasma Bovis: One New Property Tests Positive

The newly identified property... was already under a Restricted Place notice under the Biosecurity Act. More>>

Accounting Scandal: Suspension Of Fuji Xerox From All-Of-Government Contract

General Manager of New Zealand Government Procurement John Ivil says, “FXNZ has been formally suspended from the Print Technology and Associated Services (PTAS) contract and terminated from the Office Supplies contract.” More>>